Literature DB >> 27226529

High Throughput Combinatorial Formatting of PcrV Nanobodies for Efficient Potency Improvement.

Evelyn De Tavernier1, Laurent Detalle1, Erika Morizzo1, Annelies Roobrouck1, Severine De Taeye1, Melanie Rieger1, Tom Verhaeghe1, Andreia Correia1, Rob Van Hegelsom1, Rita Figueirido1, Jeroen Noens1, Søren Steffensen1, Thomas Stöhr1, Willem Van de Velde1, Erik Depla1, Bruno Dombrecht2.   

Abstract

Improving potencies through concomitant blockage of multiple epitopes and avid binding by fusing multiple (different) monovalent Nanobody building blocks via linker sequences into one multivalent polypeptide chain is an elegant alternative to affinity maturation. We explored a large and random formatting library of bivalent (combinations of two identical) and biparatopic (combinations of two different) Nanobodies for functional blockade of Pseudomonas aeruginosa PcrV. PcrV is an essential part of the P. aeruginosa type III secretion system (T3SS), and its oligomeric nature allows for multiple complex binding and blocking options. The library screening yielded a large number of promising biparatopic lead candidates, revealing significant (and non-trivial) preferences in terms of Nanobody building block and epitope bin combinations and orientations. Excellent potencies were confirmed upon further characterization in two different P. aeruginosa T3SS-mediated cytotoxicity assays. Three biparatopic Nanobodies were evaluated in a lethal mouse P. aeruginosa challenge pneumonia model, conferring 100% survival upon prophylactic administration and reducing lung P. aeruginosa burden by up to 2 logs. At very low doses, they protected the mice from P. aeruginosa infection-related changes in lung histology, myeloperoxidase production, and lung weight. Importantly, the most potent Nanobody still conferred protection after therapeutic administration up to 24 h post-infection. The concept of screening such formatting libraries for potency improvement is applicable to other targets and biological therapeutic platforms.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  PcrV; Pseudomonas aeruginosa (P. aeruginosa); avidity; biparatopic; bivalent; epitope mapping; formatting; high throughput screening (HTS); single-domain antibody (sdAb, Nanobody); type III secretion system (T3SS)

Mesh:

Substances:

Year:  2016        PMID: 27226529      PMCID: PMC4946937          DOI: 10.1074/jbc.M115.684241

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice.

Authors:  I A Holder; A N Neely; D W Frank
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

2.  Polarisation of type III translocation by Pseudomonas aeruginosa requires PcrG, PcrV and PopN.

Authors:  Charlotta Sundin; Johanna Thelaus; Jeanette E Bröms; Ake Forsberg
Journal:  Microb Pathog       Date:  2004-12-08       Impact factor: 3.738

3.  Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies.

Authors:  Rob C Roovers; Toon Laeremans; Lieven Huang; Severine De Taeye; Arie J Verkleij; Hilde Revets; Hans J de Haard; Paul M P van Bergen en Henegouwen
Journal:  Cancer Immunol Immunother       Date:  2007-03       Impact factor: 6.968

4.  A novel effector secretion mechanism based on proton-motive force-dependent type III secretion apparatus rotation.

Authors:  Takashi Ohgita; Naoki Hayashi; Susumu Hama; Hiroyuki Tsuchiya; Naomasa Gotoh; Kentaro Kogure
Journal:  FASEB J       Date:  2013-03-20       Impact factor: 5.191

Review 5.  Nanobodies: natural single-domain antibodies.

Authors:  Serge Muyldermans
Journal:  Annu Rev Biochem       Date:  2013-03-13       Impact factor: 23.643

6.  Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury.

Authors:  T Sawa; T L Yahr; M Ohara; K Kurahashi; M A Gropper; J P Wiener-Kronish; D W Frank
Journal:  Nat Med       Date:  1999-04       Impact factor: 53.440

7.  A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.

Authors:  Rob C Roovers; Maria J W D Vosjan; Toon Laeremans; Rachid el Khoulati; Renée C G de Bruin; Kathryn M Ferguson; Arie J Verkleij; Guus A M S van Dongen; Paul M P van Bergen en Henegouwen
Journal:  Int J Cancer       Date:  2011-08-08       Impact factor: 7.396

8.  The V antigen of Pseudomonas aeruginosa is required for assembly of the functional PopB/PopD translocation pore in host cell membranes.

Authors:  Julien Goure; Alexandrine Pastor; Eric Faudry; Jacqueline Chabert; Andréa Dessen; Ina Attree
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

9.  Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules.

Authors:  Anna Hultberg; Nigel J Temperton; Valérie Rosseels; Mireille Koenders; Maria Gonzalez-Pajuelo; Bert Schepens; Lorena Itatí Ibañez; Peter Vanlandschoot; Joris Schillemans; Michael Saunders; Robin A Weiss; Xavier Saelens; José A Melero; C Theo Verrips; Steven Van Gucht; Hans J de Haard
Journal:  PLoS One       Date:  2011-04-01       Impact factor: 3.240

10.  Crystal structure of PrgI-SipD: insight into a secretion competent state of the type three secretion system needle tip and its interaction with host ligands.

Authors:  Michele Lunelli; Robert Hurwitz; Jutta Lambers; Michael Kolbe
Journal:  PLoS Pathog       Date:  2011-08-04       Impact factor: 6.823

View more
  10 in total

1.  Single-domain antibodies pinpoint potential targets within Shigella invasion plasmid antigen D of the needle tip complex for inhibition of type III secretion.

Authors:  Michael L Barta; Jonathan P Shearer; Olivia Arizmendi; Jacqueline M Tremblay; Nurjahan Mehzabeen; Qi Zheng; Kevin P Battaile; Scott Lovell; Saul Tzipori; William D Picking; Charles B Shoemaker; Wendy L Picking
Journal:  J Biol Chem       Date:  2017-08-25       Impact factor: 5.157

2.  Pseudomonas aeruginosa Antivirulence Strategies: Targeting the Type III Secretion System.

Authors:  Joanna B Goldberg; Cristian V Crisan; Justin M Luu
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

3.  The constitutive activity of the virally encoded chemokine receptor US28 accelerates glioblastoma growth.

Authors:  Raimond Heukers; Tian Shu Fan; Raymond H de Wit; Jeffrey R van Senten; Timo W M De Groof; Maarten P Bebelman; Tonny Lagerweij; Joao Vieira; Sabrina M de Munnik; Laura Smits-de Vries; Jody van Offenbeek; Afsar Rahbar; Diane van Hoorick; Cecilia Söderberg-Naucler; Thomas Würdinger; Rob Leurs; Marco Siderius; Henry F Vischer; Martine J Smit
Journal:  Oncogene       Date:  2018-04-30       Impact factor: 9.867

4.  Rational Design of a Chimeric Derivative of PcrV as a Subunit Vaccine Against Pseudomonas aeruginosa.

Authors:  Chuang Wan; Jin Zhang; Liqun Zhao; Xin Cheng; Chen Gao; Ying Wang; Wanting Xu; Quanming Zou; Jiang Gu
Journal:  Front Immunol       Date:  2019-04-24       Impact factor: 7.561

Review 5.  Antibodies Inhibiting the Type III Secretion System of Gram-Negative Pathogenic Bacteria.

Authors:  Julia A Hotinger; Aaron E May
Journal:  Antibodies (Basel)       Date:  2020-07-27

6.  Vaccination of mice with hybrid protein containing Exotoxin S and PcrV with adjuvants alum and MPL protects Pseudomonas aeruginosa infections.

Authors:  Mohammad Reza Asadi Karam; Farzad Badmasti; Khadijeh Ahmadi; Mehri Habibi
Journal:  Sci Rep       Date:  2022-01-25       Impact factor: 4.379

Review 7.  Research progress and applications of nanobody in human infectious diseases.

Authors:  Yaxian Mei; Yuanzhi Chen; Jwala P Sivaccumar; Zhiqiang An; Ningshao Xia; Wenxin Luo
Journal:  Front Pharmacol       Date:  2022-08-12       Impact factor: 5.988

8.  Small Molecule Inhibitor of Type Three Secretion System Belonging to a Class 2,4-disubstituted-4H-[1,3,4]-thiadiazine-5-ones Improves Survival and Decreases Bacterial Loads in an Airway Pseudomonas aeruginosa Infection in Mice.

Authors:  Anna B Sheremet; Naylia A Zigangirova; Egor S Zayakin; Sergei I Luyksaar; Lydia N Kapotina; Ludmila N Nesterenko; Natalie V Kobets; Alexander L Gintsburg
Journal:  Biomed Res Int       Date:  2018-09-10       Impact factor: 3.411

Review 9.  Recombinant expression of nanobodies and nanobody-derived immunoreagents.

Authors:  Ario de Marco
Journal:  Protein Expr Purif       Date:  2020-04-11       Impact factor: 1.650

10.  Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment.

Authors:  Jiewen Wang; Guangbo Kang; Haibin Yuan; Xiaocang Cao; He Huang; Ario de Marco
Journal:  Front Immunol       Date:  2022-01-18       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.